BioSpace News Archive

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023, at 4:55 p.m. Eastern Time / 2:55 p.m. Mountain Time.

Mirion announced that Chief Financial Officer, Brian Schopfer, will present at the Jefferies Industrials Conference in New York, NY.

In response to a significant global unmet need for the “SUTURE-TIGHT"™ catheter, VESTECK, Inc. is expanding the International Scientific Advisory Board.

American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRF) (“Aires” or the “Company”), a leader in scientifically-proven EMF modulation technology, announces a Partnership Agreement with HUCK Project LLC (HUCK), whereby HUCK becomes the Company’s non-exclusive global retail-only distribution partner.

Bristol Myers Squibb announced that the U.S. Food and Drug Administration has approved Reblozyl® for the treatment of anemia without previous erythropoiesis stimulating agent use in adult patients with very low- to intermediate-risk myelodysplastic syndromes who may require regular red blood cell transfusions.

Delve Bio, a pioneer in metagenomic next-generation sequencing for infectious diseases, announced the appointment of Jim Stuart as chief commercial officer and Jay Wohlgemuth, M.D., to the board of directors.

National Resilience, Inc. and Lifera have entered into a non-binding term sheet for the development of biopharma manufacturing capacity in Riyadh, Saudi Arabia.

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced that management will be presenting virtually at the H.C. Wainwright 25th Annual Global Investment Conference.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today praised actions taken by the U.S. Centers for Disease Control and Prevention (CDC) aimed at optimizing hospital sepsis programs in the United States.

Cerevance has been named by Fierce Biotech as one of the most promising early-stage biotechnology companies in the industry in 2023, showcased on this year’s Fierce 15 list.